Research field (1)：
Allergies and connective tissue disease
Research keywords (5)：
rheumatoid arthritis
, immunosenescence
, SLE
, dermatomyositis
, ANCA associated vasculitis
Research theme for competitive and other funds (3)：
2022 - 2025 自己免疫疾患における加齢性クローナル造血の関連についての検討
2015 - 2018 Development of new mouse model of granulomatosis with polyangitis
2008 - 2009 Establishment of a novel mouse model to allow efficient in vivo gene transfer into hematopoietic stem cells
Papers (137)：
Koichi Kimura, Masahiro Ayano, Shun-Ichiro Ota, Kazuo Kushimoto, Yasutaka Kimoto, Hiroki Mitoma, Nobuyuki Ono, Yojiro Arinobu, Koichi Akashi, Takahiko Horiuchi, et al. Comparative efficacy and safety of belimumab and hydroxychloroquine in the maintenance phase in patients with systemic lupus erythematosus: a retrospective cohort study. Frontiers in Lupus. 2024. 2
Masahiro Ayano, Akie Hirata, Shoji Tokunaga, Hiroko Furuhashi, Yasutaka Kimoto, Nobuyuki Ono, Yojiro Arinobu, Naoki Nakashima, Koichi Akashi, Takahiko Horiuchi, et al. No clear influence of treatment escalation on flare prevention in serologically active clinically quiescent patients with systemic lupus erythematosus: a retrospective cohort study. Rheumatology International. 2024
Fumiaki Sagawa, Hisakata Yamada, Masahiro Ayano, Yasutaka Kimoto, Hiroki Mitoma, Nobuyuki Ono, Yojiro Arinobu, Masakazu Kondo, Yasuharu Nakashima, Koichi Akashi, et al. Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis. RMD Open. 2024. 10. 1. e003693-e003693
Nobuyuki Ono, Tatsuya Kai, Yukiko Takeyama, Yasushi Inoue, Naoyasu Ueda, Shuji Nagano, Shunichiro Ohta, Hisako Inoue, Takuya Sawabe, Yutaka Chifu, et al. Recent advances in the treatment strategy for AAV improved outcomes with intensive GC tapering. International Journal of Rheumatic Diseases. 2023. 27. 1
Yusuke Kashiwado, Yasutaka Kimoto, Shiro Ohshima, Takuya Sawabe, Kensuke Irino, Shota Nakano, Junki Hiura, Akiko Yonekawa, Qiaolei Wang, Goro Doi, et al. Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients. Rheumatology (Oxford, England). 2023
